The research team led by Vice President Chen Zhenyu of Taipei Medical University, with projects such as the Multimodal Lung Cancer Clinical Intelligence Decision Support Sharing System, was awarded the Ministry of Science and Technology’s 2021 Future Tech Award on September 6. From October 14 to 23, they participated in both the physical and online exhibitions at the Future Technology Pavilion at Taipei World Trade Center, Hall 1.

■ Multimodal Lung Cancer Clinical Intelligence Decision Support Sharing System: Cheng-Yu Chen, Min-Huei Hsu, Tzu-Hao Chang, Shih-Hsin Hsiao, Chi-Long Chen, Nguyen Quoc Khanh Le.

The “Multimodal Lung Cancer Clinical Intelligence Decision Support Sharing System” was developed by Professor/Vice President Cheng-Yu Chen of Taipei Medical University, Chief Information Officer Min-Huei Hsu, Director of the Information Technology Office Tzu-Hao Chang, AI Program Professor Nguyen Quoc Khanh Le, Director of the Department of Chest Medicine at Taipei Medical University Hospital Shih-Hsin Hsiao, and Professor Chi-Long Chen from the Department of Pathology, in collaboration with major Taiwanese medical technology companies, Yun Xiang Technology Co., Ltd. and Findings Technology. This initiative was part of the 2020 Ministry of Science and Technology’s Lung Cancer Big Data Precision Medicine Artificial Intelligence System project.

The technology utilizes an innovative artificial intelligence lung cancer model to assist with clinical CT and digital pathology image interpretation, combining clinical and genetic data to establish a decision support sharing system (CDSS-SDM). By following the actual disease progression in clinical practice, it provides physicians with diagnostic, precision, and graded evaluations, enabling shared decision-making between doctors and patients. The goal is to achieve clinical value and international competitiveness while promoting the development of the medical AI industry.

Lung cancer remains the leading cause of cancer-related death in Taiwan. Despite the growing availability of targeted therapies and immunotherapy drugs in recent years, the five-year survival rate for patients remains around 15%. In clinical practice, early diagnosis of lung cancer requires precise imaging, while treatment and drug selection must consider factors such as genetic mutations. To enhance healthcare efficiency and realize the vision of precise clinical pathways and treatments for lung cancer, this technology aims for “early prevention, precise diagnosis, and accurate medication.” Leveraging the high-quality clinical big data of Taipei Medical University, in collaboration with major players in the medical technology industry, this multimodal lung cancer clinical intelligence decision support system was developed with a vision for future technologies. Built on deep learning, the AI-powered platform for lung cancer big data precision medicine aims to improve clinical decision-making, offering a high-precision multimodal AI integration platform for lung cancer. This technology holds potential for application to other cancers in the future, further contributing to the flourishing of the precision medicine AI industry. (Text by: Artificial Intelligence Medical Research Center)

[Below: A photo of Vice President Cheng-Yu Chen’s research team, from left to right: Chief Information Officer Tzu-Hao Chang, Chief Data Officer Min-Huei Hsu, Professor Chi-Long Chen, Vice President Cheng-Yu Chen, Professor Nguyen Quoc Khanh Le, Director Shih-Hsin Hsiao.]